Pfizer Beats Q4 Revenue, EPS Estimates
Pharmaceuticals giant (NYSE:PFE) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. The company reported an adjusted earnings per share of $0.63, significantly above the analyst consensus of $0.47, while generating revenue of $17.76 billion, surpassing expectations of $17.35 billion.
Despite a significant year-over-year decline in Comirnaty revenue, the overall performance was strong, driven by growth in non-COVID-19 products and strategic acquisitions.
Source: Pfizer. Note: Analyst consensus estimates for the quarter provided by FactSet. N/M = Change figures are not meaningful due to a one-time, non-cash revenue reversal of $3.5 billion related to its COVID-19 antiviral Paxlovid in the fourth quarter of 2023.
Source Fool.com
Pfizer Inc. Stock
We see a rather positive sentiment for Pfizer Inc. with 15 Buy predictions and 2 Sell predictions.
As a result the target price of 29 € shows a positive potential of 25.81% compared to the current price of 23.05 € for Pfizer Inc..
